Clinical trial
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00025467 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00025467 |
|---|---|
| Title | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| Official title | A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma |
| Intervention type | Drug, Other |
| Interventions | thalidomide, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Sep 1, 2001 |
| Primary completion | Jul 1, 2007 |
| First posted | Oct 15, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: